Skip to main content

Table 2 Univariate and multivariate analyses of preoperative clinical and MRI risk factors for LNM in NF -PNETS in the training cohort

From: Preoperative prediction of lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors from clinical and MRI features: a multicenter study

Factors

Univariate analysis

Multivariate analysis

LNM-negative group (n = 45)

LNM-positive group (n = 21)

p

OR (95%CI)

p

Gender (male/female)

18/27

11/10

0.350

  

Age, year

52.87 ± 12.19

55.62 ± 12.03

0.390

  

BMI, kg/m2

24.75 ± 3.89

24.06 ± 4.40

0.520

  

Symptom (present or absent)

23/22

11/10

0.920

  

NLR (mean ± SD)

2.29 ± 1.39

3.02 ± 4.02

0.510

  

TB (< 21/ ≥ 21), μmol/L

40/5

13/6

0.070

  

ALT (< 40/ ≥ 40), IU/L

42/3

13/6

0.016

  

AST (< 40/ ≥ 40), IU/L

43/2

14/7

0.003

  

FBG (< 6.1/ ≥ 6.1), mmol/L

30/14

10/9

0.240

  

CEA (< 5/ ≥ 5), ng/ml

36/5

18/1

0.650

  

CA199 (< 37/ ≥ 37), U/ml

39/2

13/6

0.010

  

CA724 (< 5.9/ ≥ 5.9), U/ml

28/1

17/0

 > 0.999

  

NSE (< 16.3/ ≥ 16.3), ng/ml

22/9

9/6

0.510

  

Tumor location (head or neck/ body/tail)

24/12/9

10/6/5

0.900

  

SI on T2WI (hypointense/ isointense/hyperintense)

2/31/12

3/14/4

0.360

  

Maximum diameter of the tumor (< = 20/ > 20 mm)

15/30

3/18

0.106

  

Tumor margin (regular/ irregular)

29/16

6/15

0.007

4.722(1.093–20.404)

0.038*

Exophytic growth (present or absent)

23/22

13/8

0.410

  

MPDD or CBDD (present or absent)

11/34

12/9

0.009

  

Hyperenhancement at arterial phase (present or absent)

27/18

7/14

0.043

  

Homogeneity (present or absent)

33/12

9/12

0.017

  

Vascular and adjacent tissue involvement (present or absent)

6/39

9/12

0.012

  

Synchronous liver metastases

7/38

11/10

0.002

  

Long axis of the largest lymph node, mm

7.44 ± 6.25

15.52 ± 6.64

 < 0.001*

  

Short axis of the largest lymph node, mm

4.11 ± 3.26

10.05 ± 4.93

 < 0.001*

1.488(1.162–1.907)

0.002*

Ratio of the long axis to the short axis of the largest lymph node

1.87 ± 0.62

1.61 ± 0.31

0.150

  

Irregular shape of the largest lymph node (present or absent)

3/42

10/11

 < 0.001*

  

Number of the lymph nodes with the short axis > 5 mm

0.71 ± 0.87

2.24 ± 1.70

 < 0.001*

  

Number of the lymph nodes with the short axis > 10 mm

0.09 ± 0.42

0.95 ± 1.16

 < 0.001*

  

ADCmean (× 10–3 mm2/s)

1453.85 ± 314.02

1505.07 ± 755.50

0.600

  

ADCmax (× 10–3 mm2/s)

2371.39 ± 590.96

2917.76 ± 1754.11

0.350

  

ADCmin (× 10–3 mm2/s)

574.80 ± 691.29

337.94 ± 524.81

0.007

  

Tumor volume, mm3

32,301.35 ± 67,882.65

139,198.20 ± 447,799.03

0.140

  
  1. LNM  lymph node metastasis, OR odds ratio, BMI  body mass index, TB total bilirubin, ALT alanine aminotransferase, AST  aspartate aminotransferase, FBG fasting blood glucose, NLR  neutrophil–lymphocyte ratio, CEA carcinoembryonic antigen, CA199 carbohydrate antigen 199, CA724 carbohydrate antigen 724, NSE neuron-specific enolase, MPDD main pancreatic duct dilatation, CBDD common bile duct dilatation, ADC apparent diffusion coefficient
  2. *Bonferroni correction was used for multiple comparison, p < 0.0015 was considered as statistically significant for univariate logistic regression